BioStock: Toleranzia carries out directed issue of up to 42 MSEK

Biotech company Toleranzia announced last night that it has decided to carry out a directed share issue to Flerie Invest and Nordic Tender, subject to approval at an extraordinary general meeting. At the same time, Flerie Invest’s founder Thomas Eldered is proposed for election to the company’s board. The issue is expected to raise up to approximately 42 MSEK, which will be used to accelerate the development of Toleranzia’s main candidate TOL2 – a potential new treatment for the serious nerve and muscle disease myasthenia gravis.

Read the full interview with CEO Charlotte Fribert at biostock.se:

https://www.biostock.se/en/toleranzia-carries-out-directed-issue-of-up-to-42-msek/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se